Los Angeles-based Cedars-Sinai has received more than $20 million to study potential treatments for heart failure and arrhythmogenic cardiomyopathy.
The funding comes from two separate grants — each more than $10 million — from the California Institute for Regenerative Medicine, according to a Dec. 11 news release from Cedars-Sinai.
One grant will support preclinical studies that combine RNA drug TY1 with semaglutide for the treatment of heart failure. The second grant will study a treatment for arrhythmogenic cardiomyopathy, the leading cause of sudden cardiac death in athletes and young people.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
